Poly(ADP-Ribose) Polymerase Inhibitor class drugs

5 results

  • akeega

    (NIRAPARIB TOSYLATE MONOHYDRATE and ABIRATERONE ACETATE)
    Janssen Biotech, Inc.
    AKEEGA, in combination with prednisone, is indicated for adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Treatment selection should be based on an FDA-approved test for AKEEGA.
    Medication Details
    Drug Interactions

  • lynparza

    (olaparib)
    AstraZeneca Pharmaceuticals LP
    Lynparza is indicated for the maintenance treatment of BRCA-mutated advanced ovarian cancer, recurrent ovarian cancer, adjuvant treatment of high-risk early breast cancer, and metastatic breast cancer. Additionally, it treats HRR gene-mutated metastatic prostate cancer, often in combination with other therapies, using FDA-approved companion diagnostics for patient selection.
    Medication Details
    Drug Interactions

  • rubraca

    (rucaparib)
    Clovis Oncology, Inc.
    Rubraca is indicated for maintenance treatment of adult patients with BRCA-mutated recurrent ovarian, fallopian tube, or primary peritoneal cancer responding to platinum-based chemotherapy, and for treating BRCA-mutated metastatic castration-resistant prostate cancer after androgen receptor therapy and taxane chemotherapy.
    Medication Details
    Drug Interactions

  • rubraca

    (rucaparib)
    pharmaand GmbH
    Rubraca is indicated for the maintenance treatment of adults with BRCA-mutated recurrent ovarian cancer in response to platinum-based chemotherapy, and for treating BRCA-mutated metastatic castration-resistant prostate cancer after previous treatments. Selection for therapy should be guided by an FDA-approved companion diagnostic.
    Medication Details
    Drug Interactions

  • talzenna

    (talazoparib)
    Pfizer Laboratories Div Pfizer Inc
    TALZENNA is indicated for treating adult patients with BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. It is also used in combination with enzalutamide for patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
    Medication Details
    Drug Interactions